Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma

BACKGROUND: In advanced cancers, transforming growth factor-beta (TGFβ) promotes tumor growth and metastases and suppresses host antitumor immunity. GC1008 is a human anti-TGFβ monoclonal antibody that neutralizes all isoforms of TGFβ. Here, the safety and activity of GC1008 was evaluated in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Morris, John C., Tan, Antoinette R., Olencki, Thomas E., Shapiro, Geoffrey I., Dezube, Bruce J., Reiss, Michael, Hsu, Frank J., Berzofsky, Jay A., Lawrence, Donald P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949712/
https://www.ncbi.nlm.nih.gov/pubmed/24618589
http://dx.doi.org/10.1371/journal.pone.0090353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949712/
https://www.ncbi.nlm.nih.gov/pubmed/24618589
http://dx.doi.org/10.1371/journal.pone.0090353

Ejemplares similares